Key Highlights
- GSK will pay $10.6 billion in cash to acquire Nuvalent at $124 per share
- Shareholders receive a 40% premium above Monday’s market close
- Nuvalent shares surged 39% to $122.90 during Tuesday’s opening session
- GSK secures three non-small cell lung cancer drug candidates, with two pending FDA reviews in late 2026
- This represents GSK’s biggest buyout in more than ten years
British pharmaceutical giant GSK revealed on Tuesday its plan to purchase Boston-headquartered oncology developer Nuvalent for $10.6 billion in an all-cash transaction, propelling Nuvalent shares 39% higher to $122.90.
The $124-per-share purchase price delivers a substantial 40% premium compared to Nuvalent’s Monday closing value. GSK’s American depositary receipts remained essentially unchanged at $50.65, though GSK’s London-traded shares fell more than 3%.
This transaction stands as GSK’s most significant buyout in more than a decade, signaling a dramatic strategic realignment for the UK-based pharmaceutical company.
With this purchase, GSK acquires three clinical-stage non-small cell lung cancer programs. The flagship candidates include zidesamtinib, designed to target ROS1 mutations, alongside neladalkib, which functions as an ALK inhibitor.
Both therapies have advanced to late-stage clinical development and are currently awaiting FDA regulatory verdicts. The agency’s decisions are scheduled for September 18 and November 27, 2026, respectively.
The portfolio also includes NVL-330, a HER2 inhibitor presently undergoing phase I clinical testing.
“These two flagship products represent potentially best-in-class therapies that could reach the market this year pending FDA approval,” stated GSK CEO Luke Miels.
GSK’s Bold Re-Entry Into Cancer Treatment
GSK had previously divested its oncology division to Novartis in exchange for Novartis’ vaccine business in 2014. This acquisition signals a definitive strategic return to cancer therapeutics as a priority area.
Miels, who assumed the CEO position in early 2026, had previously communicated to shareholders a strategic focus on acquisitions valued between £2 billion and £4 billion. He defended the elevated acquisition price by emphasizing that the transaction effectively secures three separate drug programs in one deal.
After accounting for cash assets acquired, GSK’s net financial commitment stands at approximately $9.4 billion. The company plans to finance the deal through a combination of new and existing debt arrangements plus available cash reserves, with no anticipated negative effect on its credit rating.
Financial Implications for GSK
GSK confirmed that its current 2026 full-year financial projections remain intact. The pharmaceutical company anticipates the acquisition will begin contributing to revenue growth and core operating profit starting in 2027, with measurable positive effects on core earnings per share materializing by 2029.
GSK also indicated the acquisition would help bolster core operating profit during the dolutegravir patent expiration window spanning 2028 through 2030.
The transaction is projected to expedite GSK’s market entry into lung cancer therapeutics while establishing a foundation for continued expansion alongside Ris-Rez, its B7-H3 antibody-drug conjugate currently advancing through phase III trials.
Pending standard regulatory clearances, including Hart-Scott-Rodino Act approval, both organizations anticipate completing the transaction prior to the conclusion of Q3 2026.
The FDA’s regulatory determinations on Nuvalent’s two primary drug candidates are set for September 18 and November 27, 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
